| 23003 |
Voclosporin |
Lupkynis® |
Voclosporin is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). |
NCPE Assessment Process Complete |
5th December 2024 |
 |
| 25059 |
Vorasidenib |
Voranigo® |
Vorasidenib (Voranigo®) is indicated as monotherapy for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy. |
Full HTA submission received from Applicant |
5th May 2026 |
|
| 19041 |
Voretigene neparvovec |
Luxturna® |
For the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| - |
Vortioxetine |
Brintellix® |
For the treatment of major depressive episodes in adults. |
Assessment process complete |
18th November 2016 |
|
| 22028 |
Vosoritide |
Voxzogo® |
For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed. |
NCPE Assessment Process Complete |
5th October 2023 |
|
| 23035 |
Vutrisiran |
Amvuttra® |
Indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy |
Rapid Review complete |
5th June 2024 |
|
| - |
Zanamivir |
Dectova® |
For the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient |
Rapid review complete |
18th October 2019 |
|
| 23072 |
Zanubrutinib |
Brukinsa® |
Zanubrutinib monotherapy is indicated for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. |
NCPE Assessment Process Complete |
3rd September 2025 |
|
| 21044 |
Zanubrutinib |
Brukinsa® |
Monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy |
Rapid review complete |
16th November 2021 |
|
| 23010 |
Zanubrutinib |
Brukinsa® |
Zanubrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). The place in therapy for zanubrutinib, proposed by the Applicant, is narrower than the licensed population i.e. as monotherapy for patients with CLL, who are treatment naïve and have del(17p) and/or TP53 mutations or for patients that have relapsed and/or refractory disease |
Rapid Review Complete |
20th October 2023 |
|
| 26024 |
Zilucoplan |
Zilbrysq® |
Zilucoplan (Zilbrysq®) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are all anti-acetylcholine receptor (AChR) antibody positive. |
Rapid Review Complete |
27th May 2026 |
|
